Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
09 Sep 2017 ESMO 2017: Front-Line Osimertinib Poised to Become Standard of Care in EGFR-Mutation Positive NSCLC Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy
09 Sep 2017 ESMO 2017: Durvalumab as Consolidation Therapy Prolongs PFS in Stage III NSCLC Patients Without Progression Following Platinum-based Chemoradiotherapy Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
09 Sep 2017 ESMO 2017: Large Dataset of Targetable Genomic Alterations Created Using Liquid Biopsy Translational research
09 Sep 2017 ESMO 2017: Subtypes of Thymic Carcinomas Show Different Genomic Alterations and Tumour Mutational Burden Endocrine and neuroendocrine tumours - Translational research
09 Sep 2017 ESMO 2017: Tumour Subtype Specific Genetic Alterations Detected by Comprehensive Genomic Profiling Translational research
09 Sep 2017 ESMO 2017: Sub-study of the GAND-Emesis Trial with Neurokinin-1 Receptor Antagonist During Concomitant Chemoradiotherapy for Cervical Cancer Palliative and supportive care
09 Sep 2017 ESMO 2017: Clinical Trial Toxicity Reporting by Investigators May Not Reflect Patients’ Viewpoint Palliative and supportive care
09 Sep 2017 ESMO 2017: Adjuvant Imatinib Recommended Only for Patients with High-risk GIST Sarcomas - Anticancer agents & Biologic therapy
09 Sep 2017 ESMO 2017: Promising Response Rates in Patients with Metastatic TNBC Treated with Nivolumab After Induction Treatment Breast cancer - Cancer Immunology and Immunotherapy
09 Sep 2017 ESMO 2017: Promising Results Demonstrated with DCC-2618 in GIST Sarcomas - Anticancer agents & Biologic therapy
09 Sep 2017 ESMO 2017: TIL Levels Signal Pembrolizumab Response in Metastatic TNBC Breast cancer - Cancer Immunology and Immunotherapy
09 Sep 2017 ESMO 2017: Overall Survival Benefit is Seen with Olaparib in Patients with Ovarian Cancer and TP53 Disruptive Mutation Status Gynaecologic malignancies - Anticancer agents & Biologic therapy
09 Sep 2017 ESMO 2017: Progression-free Rate Unaffected by Sequence of Cytoreductive Nephrectomy and Sunitinib in Patients with Synchronous mRCC Genitourinary cancers - Anticancer agents & Biologic therapy
09 Sep 2017 ESMO 2017 Media Alert: Hot Topic at ESMO 2017: Session Focuses on Adjuvant Chemotherapy Duration in Colon Cancer
09 Sep 2017 ESMO 2017 Press Release: Durvalumab Improves Progression-free Survival in Stage III Lung Cancer Lung and other thoracic tumours